|
Total number of AEs found NE group: n = 150; E group: n = 75
|
2 (1.3%)
|
14 (18.7%)
|
OR 16.8; 95% CI: 3.7-76.9; p < 0.001
|
|
Number of AEs excluding patients with viral load > 50 copies/mL at visit −1 NE group: n = 141; E group: n = 62
|
2 (1.4%)
|
11 (17.7%)
|
OR 14.9; 95% CI: 3.2-70.0; p < 0.001
|
|
Number of AEs excluding patients with viral load > 50 copies/mL at baseline visit NE group: n = 136; E group: n = 64
|
2 (1.5%)
|
13 (20.3%)
|
OR 17.0; 95% CI: 3.7-78.3; p < 0.001
|
|
Number of AEs excluding patients who recently started treatment with FDCs NE group: n = 132; E group: n = 63
|
1 (0.8%)
|
11 (17.5%)
|
OR 27.1; 95% CI: 3.4-215.8; p < 0.001
|
|
Number of AEs excluding patients who recently started treatment with efavirenz NE group: n = 84; E group: n = 50
|
2 (2.4%)
|
12 (24.0%)
|
OR 13.5; 95% CI: 2.9-63.5; p < 0.001
|
